Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key-Reference-Cited by-同舟云学术

Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key

Published:2008-01 Issue:1 Volume:9 Page:1-4
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Payne Katherine¹²

Affiliation:

1. The University of Manchester, Health Economics Research at Manchester (HERMAN), Health Methodology Research Group, School of Community Based Medicine, University Place, Oxford Road, Manchester, M13 9PL, UK

2. The Nowgen Centre, Nowgen – A Centre for Genetics in Healthcare, 29 Grafton Street, Manchester, M13 9WU, UK.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/14622416.9.1.1

Reference25 articles.

1. The Royal Society: Personalised medicines: Hopes and Realities. London, UK (2005).

2. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription

3. Pharmacogenomics of Anticancer Agents: Implications for Clinical Pharmacy Practice

4. DrummondM, Sculpher M, Torrance GW, O’Brien BJ, Stoddart G: Methods For the Economic Evaluation of Health Care Programmes. 3rd Revised Edition. Oxford University Press, Oxford, UK (2005).

5. National Institute for Health and Clinical Excellence: a Guide to Technology Appraisals. NICE, London, UK (2004).

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proposed models for genetic counseling: Which quality indicators by Donabedian's model are more feasible?;Acta Facultatis Medicae Naissensis;2020

2. Using Cost-Effectiveness Analysis to Quantify the Value of Genomic-Based Diagnostic Tests: Recommendations for Practice and Research;Genetic Testing and Molecular Biomarkers;2017-12

3. Health Economic Perspectives of Genomics;Genomics and Society;2016

4. Special Requirements for Economic Evaluation and Health Technology Assessment in Genomic Medicine;Economic Evaluation in Genomic Medicine;2015

5. Issues surrounding the health economic evaluation of genomic technologies;Pharmacogenomics;2013-11